The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework
To complement real‐world evidence (RWE) guidelines, the 2019 Structured Preapproval and Postapproval Comparative study design framework to generate valid and transparent real‐world Evidence (SPACE) framework elucidated a process for designing valid and transparent real‐world studies. As an extension...
Gespeichert in:
Veröffentlicht in: | Clinical pharmacology and therapeutics 2022-01, Vol.111 (1), p.122-134 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 134 |
---|---|
container_issue | 1 |
container_start_page | 122 |
container_title | Clinical pharmacology and therapeutics |
container_volume | 111 |
creator | Gatto, Nicolle M. Campbell, Ulka B. Rubinstein, Emily Jaksa, Ashley Mattox, Pattra Mo, Jingping Reynolds, Robert F. |
description | To complement real‐world evidence (RWE) guidelines, the 2019 Structured Preapproval and Postapproval Comparative study design framework to generate valid and transparent real‐world Evidence (SPACE) framework elucidated a process for designing valid and transparent real‐world studies. As an extension to SPACE, here, we provide a structured framework for conducting feasibility assessments—a step‐by‐step guide to identify decision grade, fit‐for‐purpose data, which complements the United States Food and Drug Administration (FDA)’s framework for a RWE program. The process was informed by our collective experience conducting systematic feasibility assessments of existing data sources for pharmacoepidemiology studies to support regulatory decisions. Used with the SPACE framework, the Structured Process to Identify Fit‐For‐Purpose Data (SPIFD) provides a systematic process for conducting feasibility assessments to determine if a data source is fit for decision making, helping ensure justification and transparency throughout study development, from articulation of a specific and meaningful research question to identification of fit‐for‐purpose data and study design. |
doi_str_mv | 10.1002/cpt.2466 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9299818</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2590079278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4766-33e1b4644333cc07da549094ab91fd272731b3864944bf1671aed51ccc1918573</originalsourceid><addsrcrecordid>eNp1kctO3DAUhi3UCgZaiSdAXnYT8C12zAJpNCWAhNSROl1bjuOAIRkPttPR7HgEnpEnwVxFF92coyN_5_ORfgD2MTrECJEjs0qHhHG-BSa4pKTgJS2_gAlCSBaSUL4DdmO8ySOTVbUNdigTmEuJJqBdXFv4O4XRpDHYFs6DNzZGmDy8aO0yuW4Da5ce7x9qH3Kdj2Hlo4U_ddLHcPrSYW11dI3rXdrAaYx5f8irsA56sGsfbr-Br53uo_3-1vfAn_p0MTsvLn-dXcyml4VhgvOCUosbxhmjlBqDRKtLJpFkupG4a4kgguKGVpxJxpoOc4G1bUtsjMESV6Wge-Dk1bsam8G2Jh8RdK9WwQ06bJTXTv37snTX6sr_VZJIWeEqC368CYK_G21ManDR2L7XS-vHqEgpERKSiE-oCT7GYLuPbzBSz6GoHIp6DiWjB5_P-gDfU8hA8QqsXW83_xWp2XzxInwC93yYWw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2590079278</pqid></control><display><type>article</type><title>The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Gatto, Nicolle M. ; Campbell, Ulka B. ; Rubinstein, Emily ; Jaksa, Ashley ; Mattox, Pattra ; Mo, Jingping ; Reynolds, Robert F.</creator><creatorcontrib>Gatto, Nicolle M. ; Campbell, Ulka B. ; Rubinstein, Emily ; Jaksa, Ashley ; Mattox, Pattra ; Mo, Jingping ; Reynolds, Robert F.</creatorcontrib><description>To complement real‐world evidence (RWE) guidelines, the 2019 Structured Preapproval and Postapproval Comparative study design framework to generate valid and transparent real‐world Evidence (SPACE) framework elucidated a process for designing valid and transparent real‐world studies. As an extension to SPACE, here, we provide a structured framework for conducting feasibility assessments—a step‐by‐step guide to identify decision grade, fit‐for‐purpose data, which complements the United States Food and Drug Administration (FDA)’s framework for a RWE program. The process was informed by our collective experience conducting systematic feasibility assessments of existing data sources for pharmacoepidemiology studies to support regulatory decisions. Used with the SPACE framework, the Structured Process to Identify Fit‐For‐Purpose Data (SPIFD) provides a systematic process for conducting feasibility assessments to determine if a data source is fit for decision making, helping ensure justification and transparency throughout study development, from articulation of a specific and meaningful research question to identification of fit‐for‐purpose data and study design.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.2466</identifier><identifier>PMID: 34716990</identifier><language>eng</language><publisher>United States: John Wiley and Sons Inc</publisher><subject>COVID-19 - drug therapy ; Data Collection ; Decision Making ; Feasibility Studies ; Humans ; Research Design ; Review ; Reviews ; Varenicline - adverse effects</subject><ispartof>Clinical pharmacology and therapeutics, 2022-01, Vol.111 (1), p.122-134</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4766-33e1b4644333cc07da549094ab91fd272731b3864944bf1671aed51ccc1918573</citedby><cites>FETCH-LOGICAL-c4766-33e1b4644333cc07da549094ab91fd272731b3864944bf1671aed51ccc1918573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.2466$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.2466$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34716990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gatto, Nicolle M.</creatorcontrib><creatorcontrib>Campbell, Ulka B.</creatorcontrib><creatorcontrib>Rubinstein, Emily</creatorcontrib><creatorcontrib>Jaksa, Ashley</creatorcontrib><creatorcontrib>Mattox, Pattra</creatorcontrib><creatorcontrib>Mo, Jingping</creatorcontrib><creatorcontrib>Reynolds, Robert F.</creatorcontrib><title>The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>To complement real‐world evidence (RWE) guidelines, the 2019 Structured Preapproval and Postapproval Comparative study design framework to generate valid and transparent real‐world Evidence (SPACE) framework elucidated a process for designing valid and transparent real‐world studies. As an extension to SPACE, here, we provide a structured framework for conducting feasibility assessments—a step‐by‐step guide to identify decision grade, fit‐for‐purpose data, which complements the United States Food and Drug Administration (FDA)’s framework for a RWE program. The process was informed by our collective experience conducting systematic feasibility assessments of existing data sources for pharmacoepidemiology studies to support regulatory decisions. Used with the SPACE framework, the Structured Process to Identify Fit‐For‐Purpose Data (SPIFD) provides a systematic process for conducting feasibility assessments to determine if a data source is fit for decision making, helping ensure justification and transparency throughout study development, from articulation of a specific and meaningful research question to identification of fit‐for‐purpose data and study design.</description><subject>COVID-19 - drug therapy</subject><subject>Data Collection</subject><subject>Decision Making</subject><subject>Feasibility Studies</subject><subject>Humans</subject><subject>Research Design</subject><subject>Review</subject><subject>Reviews</subject><subject>Varenicline - adverse effects</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctO3DAUhi3UCgZaiSdAXnYT8C12zAJpNCWAhNSROl1bjuOAIRkPttPR7HgEnpEnwVxFF92coyN_5_ORfgD2MTrECJEjs0qHhHG-BSa4pKTgJS2_gAlCSBaSUL4DdmO8ySOTVbUNdigTmEuJJqBdXFv4O4XRpDHYFs6DNzZGmDy8aO0yuW4Da5ce7x9qH3Kdj2Hlo4U_ddLHcPrSYW11dI3rXdrAaYx5f8irsA56sGsfbr-Br53uo_3-1vfAn_p0MTsvLn-dXcyml4VhgvOCUosbxhmjlBqDRKtLJpFkupG4a4kgguKGVpxJxpoOc4G1bUtsjMESV6Wge-Dk1bsam8G2Jh8RdK9WwQ06bJTXTv37snTX6sr_VZJIWeEqC368CYK_G21ManDR2L7XS-vHqEgpERKSiE-oCT7GYLuPbzBSz6GoHIp6DiWjB5_P-gDfU8hA8QqsXW83_xWp2XzxInwC93yYWw</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Gatto, Nicolle M.</creator><creator>Campbell, Ulka B.</creator><creator>Rubinstein, Emily</creator><creator>Jaksa, Ashley</creator><creator>Mattox, Pattra</creator><creator>Mo, Jingping</creator><creator>Reynolds, Robert F.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202201</creationdate><title>The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework</title><author>Gatto, Nicolle M. ; Campbell, Ulka B. ; Rubinstein, Emily ; Jaksa, Ashley ; Mattox, Pattra ; Mo, Jingping ; Reynolds, Robert F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4766-33e1b4644333cc07da549094ab91fd272731b3864944bf1671aed51ccc1918573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>COVID-19 - drug therapy</topic><topic>Data Collection</topic><topic>Decision Making</topic><topic>Feasibility Studies</topic><topic>Humans</topic><topic>Research Design</topic><topic>Review</topic><topic>Reviews</topic><topic>Varenicline - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gatto, Nicolle M.</creatorcontrib><creatorcontrib>Campbell, Ulka B.</creatorcontrib><creatorcontrib>Rubinstein, Emily</creatorcontrib><creatorcontrib>Jaksa, Ashley</creatorcontrib><creatorcontrib>Mattox, Pattra</creatorcontrib><creatorcontrib>Mo, Jingping</creatorcontrib><creatorcontrib>Reynolds, Robert F.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gatto, Nicolle M.</au><au>Campbell, Ulka B.</au><au>Rubinstein, Emily</au><au>Jaksa, Ashley</au><au>Mattox, Pattra</au><au>Mo, Jingping</au><au>Reynolds, Robert F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2022-01</date><risdate>2022</risdate><volume>111</volume><issue>1</issue><spage>122</spage><epage>134</epage><pages>122-134</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>To complement real‐world evidence (RWE) guidelines, the 2019 Structured Preapproval and Postapproval Comparative study design framework to generate valid and transparent real‐world Evidence (SPACE) framework elucidated a process for designing valid and transparent real‐world studies. As an extension to SPACE, here, we provide a structured framework for conducting feasibility assessments—a step‐by‐step guide to identify decision grade, fit‐for‐purpose data, which complements the United States Food and Drug Administration (FDA)’s framework for a RWE program. The process was informed by our collective experience conducting systematic feasibility assessments of existing data sources for pharmacoepidemiology studies to support regulatory decisions. Used with the SPACE framework, the Structured Process to Identify Fit‐For‐Purpose Data (SPIFD) provides a systematic process for conducting feasibility assessments to determine if a data source is fit for decision making, helping ensure justification and transparency throughout study development, from articulation of a specific and meaningful research question to identification of fit‐for‐purpose data and study design.</abstract><cop>United States</cop><pub>John Wiley and Sons Inc</pub><pmid>34716990</pmid><doi>10.1002/cpt.2466</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-9236 |
ispartof | Clinical pharmacology and therapeutics, 2022-01, Vol.111 (1), p.122-134 |
issn | 0009-9236 1532-6535 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9299818 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | COVID-19 - drug therapy Data Collection Decision Making Feasibility Studies Humans Research Design Review Reviews Varenicline - adverse effects |
title | The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T05%3A13%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Structured%20Process%20to%20Identify%20Fit%E2%80%90For%E2%80%90Purpose%20Data:%20A%20Data%20Feasibility%20Assessment%20Framework&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Gatto,%20Nicolle%20M.&rft.date=2022-01&rft.volume=111&rft.issue=1&rft.spage=122&rft.epage=134&rft.pages=122-134&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.2466&rft_dat=%3Cproquest_pubme%3E2590079278%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2590079278&rft_id=info:pmid/34716990&rfr_iscdi=true |